187 related articles for article (PubMed ID: 25117153)
41. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
Hammond-Thelin LA
Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
[TBL] [Abstract][Full Text] [Related]
42. Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
Arrondeau J; Huillard O; Tlemsani C; Cessot A; Boudou-Rouquette P; Blanchet B; Thomas-Schoemann A; Vidal M; Tigaud JM; Durand JP; Alexandre J; Goldwasser F
Expert Opin Investig Drugs; 2015 May; 24(5):673-87. PubMed ID: 25599887
[TBL] [Abstract][Full Text] [Related]
43. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
44. Non-rash skin toxicities associated with novel targeted therapies.
Lacouture ME; Boerner SA; Lorusso PM
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S36-42. PubMed ID: 17239289
[TBL] [Abstract][Full Text] [Related]
45. Targeted therapies: a new generation of cancer treatments.
Gerber DE
Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955
[TBL] [Abstract][Full Text] [Related]
46. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood.
Sanborn RE; Sauer DA
Dermatol Clin; 2008 Jan; 26(1):103-19, ix. PubMed ID: 18023774
[TBL] [Abstract][Full Text] [Related]
47. Targeting FGFR Signaling in Cancer.
Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
[TBL] [Abstract][Full Text] [Related]
48. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
49. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management.
Liu S; Kurzrock R
Semin Oncol; 2015 Dec; 42(6):863-75. PubMed ID: 26615131
[TBL] [Abstract][Full Text] [Related]
50. Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications.
Zur E
Int J Pharm Compd; 2018; 22(6):446-454. PubMed ID: 30384344
[TBL] [Abstract][Full Text] [Related]
51. Skin care for cancer patients.
Lacouture ME
Clin Adv Hematol Oncol; 2012 Nov; 10(11):748-50. PubMed ID: 23271263
[No Abstract] [Full Text] [Related]
52. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
53. Prevention and management of major side effects of targeted agents in breast cancer.
Metzger Filho O; Saini KS; Azim HA; Awada A;
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e79-85. PubMed ID: 20817545
[TBL] [Abstract][Full Text] [Related]
54. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
55. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.
Dreno B; Bensadoun RJ; Humbert P; Krutmann J; Luger T; Triller R; Rougier A; Seité S
J Eur Acad Dermatol Venereol; 2013 Sep; 27(9):1071-80. PubMed ID: 23368717
[TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
Bianchini D; Jayanth A; Chua YJ; Cunningham D
Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
[TBL] [Abstract][Full Text] [Related]
57. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.
Chan A; Cameron MC; Garden B; Boers-Doets CB; Schindler K; Epstein JB; Choi J; Beamer L; Roeland E; Russi EG; Bensadoun RJ; Teo YL; Chan RJ; Shih V; Bryce J; Raber-Durlacher J; Gerber PA; Freytes CO; Rapoport B; LeBoeuf N; Sibaud V; Lacouture ME
Support Care Cancer; 2015 Aug; 23(8):2231-44. PubMed ID: 25564221
[TBL] [Abstract][Full Text] [Related]
58. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.
Lacouture ME
Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987
[TBL] [Abstract][Full Text] [Related]
59. Cutaneous reactions to pediatric cancer treatment: Part I. Conventional chemotherapy.
Sous D; Armstrong AE; Huang JT; Shah S; Carlberg VM; Coughlin CC
Pediatr Dermatol; 2021 Jan; 38(1):8-17. PubMed ID: 33170534
[TBL] [Abstract][Full Text] [Related]
60. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
Santhosh S; Kumar P; Ramprasad V; Chaudhuri A
Future Oncol; 2015; 11(2):279-93. PubMed ID: 25591839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]